sorafenib has been researched along with Fanconi Anemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Huang, S; Jiang, J; Lü, M; Luo, B; Ren, W; Shi, L; Shi, X; Tang, X; Zhang, W; Zhong, X | 1 |
1 other study(ies) available for sorafenib and Fanconi Anemia
| Article | Year |
|---|---|
FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |